Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Colorectal Neoplasms 32Ovarian Neoplasms 21Neoplasms 14Carcinoma, Hepatocellular 13Fallopian Tube Neoplasms 12Carcinoma, Non-Small-Cell Lung 9Endometrial Neoplasms 7Colonic Neoplasms 7Neoplasm Metastasis 6Squamous Cell Carcinoma of Head and Neck 4Glioblastoma 4Breast Neoplasms 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Biliary Tract Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neuroma, Acoustic 2Neurofibromatosis 2 2Mouth Neoplasms 2Meningioma 2Lymphoid Interstitial Pneumonia 2Gastrointestinal Neoplasms 2Digestive System Neoplasms 2

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Bevacizumab × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡